Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to ImatinibHélène Labussière, Franck E. Nicolini, Quoc‐Hung Le et al.|Blood|2008Cited by 11
A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 scheduleOlfa Derbel, Xavier Thomas, Giovanna Cannas et al.|Hematology|2010Cited by 2